Literature DB >> 25770987

A prospective randomized study of heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access.

David Shemesh1, Ilya Goldin2, Jamal Hijazi2, Ibrahim Zaghal3, Daniel Berelowitz3, Anthony Verstandig3, Oded Olsha2.   

Abstract

OBJECTIVE: Prosthetic grafts continue to be required for hemodialysis access when the options for native fistulas have been exhausted. The inferior long-term patency of grafts makes the possibility of preventing occlusion with heparin-bonded grafts an attractive alternative. We carried out a prospective randomized study to compare the patency of standard grafts with heparin-bonded grafts.
METHODS: Patients with end-stage renal failure requiring a prosthetic access were randomized to receive either a standard expanded polytetrafluorethylene (ePTFE) graft or a heparin-bonded ePTFE graft. Patients were enrolled from June 2007 until November 2011 and were followed up until July 2013, when the study concluded.
RESULTS: In this study, 160 patients were randomized and followed up for a median of 23.5 months. No patient was lost to follow-up. Primary patency was 35% and 14% for heparin-bonded grafts and 29% and 12% for standard ePTFE grafts at 6 and 12 months, respectively (P = .48). Assisted primary patency was 54%, 41%, and 27% for heparin-bonded grafts and 41%, 30%, and 23% for standard grafts at 12, 24, and 36 months, respectively (P = .12). Secondary patency was 83%, 83%, and 81% for heparin-bonded grafts and 81%, 73%, and 68% for standard grafts at 12, 24, and 36 months, respectively (P = .33). There were significantly fewer thromboses in heparin-bonded grafts during the first 5 months (P = .020). Of 80 standard grafts, 24 were eventually abandoned vs 17 heparin-bonded grafts (P = .188). Bleeding complications, infections, and intervention rates were similar in both groups.
CONCLUSIONS: Heparin-bonded grafts demonstrated a trend to improved patency, but the difference was not statistically significant. Heparin-bonded grafts had a significantly lower early thrombosis rate that was sustained only for the first 5 months of follow-up.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25770987     DOI: 10.1016/j.jvs.2015.01.056

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

Review 1.  Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-Analysis.

Authors:  Ronald J Halbert; Gina Nicholson; Robert J Nordyke; Alison Pilgrim; Laura Niklason
Journal:  Kidney360       Date:  2020-10-15

2.  The formulation and characterization of 3D printed grafts as vascular access for potential use in hemodialysis.

Authors:  Bill Cheng; Yue-Min Xing; Nai-Chia Shih; Jen-Po Weng; Hsin-Chieh Lin
Journal:  RSC Adv       Date:  2018-04-24       Impact factor: 4.036

Review 3.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

4.  Hemocompatibility of hyaluronan enhanced linear low density polyethylene for blood contacting applications.

Authors:  Rachael Simon-Walker; John Cavicchia; David A Prawel; Lakshmi Prasad Dasi; Susan P James; Ketul C Popat
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2017-09-30       Impact factor: 3.368

5.  Cellular remodeling of fibrotic conduit as vascular graft.

Authors:  Xuefeng Qiu; Benjamin Li-Ping Lee; Sze Yue Wong; Xili Ding; Kang Xu; Wen Zhao; Dong Wang; Ryan Sochol; Nianguo Dong; Song Li
Journal:  Biomaterials       Date:  2020-12-01       Impact factor: 12.479

Review 6.  Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering.

Authors:  Hannah A Strobel; Elisabet I Qendro; Eben Alsberg; Marsha W Rolle
Journal:  Front Pharmacol       Date:  2018-11-21       Impact factor: 5.810

Review 7.  Arteriovenous access in hemodialysis: A multidisciplinary perspective for future solutions.

Authors:  Bernd Stegmayr; Christian Willems; Thomas Groth; Albino Martins; Nuno M Neves; Khosrow Mottaghy; Andrea Remuzzi; Beat Walpoth
Journal:  Int J Artif Organs       Date:  2020-05-22       Impact factor: 1.595

8.  In situ regeneration of bioactive coatings enabled by an evolved Staphylococcus aureus sortase A.

Authors:  Hyun Ok Ham; Zheng Qu; Carolyn A Haller; Brent M Dorr; Erbin Dai; Wookhyun Kim; David R Liu; Elliot L Chaikof
Journal:  Nat Commun       Date:  2016-04-13       Impact factor: 14.919

9.  Maintaining Patency of Vascular Access for Haemodialysis.

Authors:  Nicholas Inston; J Al Shakarchi; A Khawaja; R Jones
Journal:  Cardiovasc Eng Technol       Date:  2017-07-18       Impact factor: 2.495

10.  Experimental comparative study of thrombogenicity of two differently luminal heparinized ePTFE vascular prosthetics.

Authors:  Mads Liisberg; Michael Stenger; Carsten Behr-Rasmussen; Jane Stubbe; Jes S Lindholt
Journal:  Ann Med Surg (Lond)       Date:  2018-09-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.